Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate

International Journal of Biological Sciences

Volumn 6, Issue 7, 2010, Pages 639-648

  Pan, Ke ^a   Zhao, Jing Jing ^a   Wang, Hui ^a   Li, Jian Jun ^a   Liang, Xiao Ting ^a   Sun, Jian Cong ^a   Chen, Yi Bing ^a   Ma, Hai Qing ^a   Liu, Qing ^a   Xia, Jian Chuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cytotoxic T cells; Dendrtic cells; Hepatocellular carcinoma; Tumor lysate; Tumor total RNA

Indexed keywords

EID: 78650568200     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.6.639     Document Type: Article

References (39)

1. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32 (1 Suppl): 225-237.
2. DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
3. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23: 2892-2899.
4. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220: 129-150.
5. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296-306
6. Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarrière N, et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res. 2006; 12: 7380-7388.
7. Wierecky J, Müller MR, Wirths S, Halder-Oehler E, Dörfel D, Schmidt SM, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 2006; 66: 5910-5918.
8. Lee WC, Wang HC, Jeng LB, Chiang YJ, Lia CR, Huang PF, et al. Effective treatment of small murine hepatocellular carcinoma by dendritic cells. Hepatology 2001; 34: 896-905.
9. Wang XH, Qin Y, Hu MH, Xie Y. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother 2005; 54: 971-980.
10. Iwashita Y, Tahara K, Goto S, Sasaki A, Kai S, Seike M, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother 2003; 52: 155-161.
11. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005; 28: 496-504.
12. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009; 49:124-132.
13. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475-480.
14. Jackson AM, Mulcahy LA, Zhu XW, O'Donnell D, Patel PM. Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int J Cancer 2008; 123: 623-632.
15. Yang DH, Park JS, Jin CJ, Kang HK, Nam JH, Rhee JH, et al. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res 2009; 33: 665-670.
16. Hatfield P, Merrick AE, West E, O'Donnell D, Selby P, Vile R, et al. Optimization of Dendritic Cell Loading With Tumor Cell Lysates for Cancer. Immunotherapy. J Immunother 2008; 31: 620-632.
17. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117: 1195-1203.
18. Tyagi RK, Mangal S, Garg N, Sharma PK. RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells. Expert Rev Anticancer Ther 2009; 9: 97-114.
19. Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006; 55: 1432-1442.
20. Grünebach F, Müller MR, Brossart P. New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol Immunother 2005; 54: 517-525.
21. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199: 251-263.
22. Nair S, Boczkowski D. RNA-transfected dendritic cells. Expert Rev Vaccines 2002; 1: 507-513.
23. Mitchell DA, Nair SK. RNA transfected dendritic cells as cancer vaccines. Curr Opin Mol Ther 2000; 2: 176-181.
24. Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000; 106:1065-1069.
25. Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001; 61: 6445-6450.
26. Clark R, Kupper T. Old meets new: the interaction between innate and adaptive immunity. J Invest Dermatol 2005; 125: 629-637.
27. Reise Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6: 476-483.
28. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3: 984-993.
29. Baxter AG, Hodgkin PD. Activation rules: The two-signal theories of immune activation. Nat Rev Immunol 2002; 2:439-446.
30. Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol. 1999; 162: 3256-3262.
31. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999; 20: 561-567.
32. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 2008; 123: 326-338.
33. Trinchieri. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Reviews Immunology 2003; 3: 133-146.
34. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105.
35. Ma X, Chow JM, Gri G, Carra G, Gerosa F, Wolf SF, et al. The interleukin-12 p40 gene promoter is primed by interferon-? in monocytic cells. J Exp Med 1996;183: 147-157.
36. Yoshida A, Koide Y, Uchijima M, Yoshida TO. IFN-? induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem Biophys Res Commun 1994;198: 857-861.
37. Ohteki T, Fukao T, Suzue K, Maki C, Ito M, Nakamura M, et al. Interleukin-12-dependent interferon? production by CD8a+ lymphoid dendritic cells. J Exp Med 1999; 189: 1981-1986.
38. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A, et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand- treated mice. J Immunol 1997; 159: 2222-2231.
39. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S. IFN-? production by antigen-presenting cells: mechanisms emerge. Trends Immunol 2001; 22: 556-560